Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Oral Probiotics Streptococcus Salivarius K12 and Lactobacillus Brevis CD2 on the Prevention of Secondary Bacterial Pneumonia in Patients With Severe COVID-19: a Phase II Randomized Clinical Trial

NCT05175833 is registered in ClinicalTrials.gov with Universidade de Passo Fundo as lead sponsor.

NCT NCT05175833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05175833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Oral Probiotics Streptococcus Salivarius K12 and Lactobacillus Brevis CD2 on the Prevention of Secondary Bacterial Pneumonia in Patients With Severe COVID-19: a Phase II Randomized Clinical Trial
Lead sponsor
Universidade de Passo Fundo
Phase
Phase 2
Overall status
Completed
Start date
September 11, 2020
Completion date
February 7, 2021
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 lower respiratory infection, microbial colonization, secondary bacterial pneumonia, severe covid-19